1-9 of 9
John Allan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Comparative analysis of characteristics and outcomes in CD5+/FMC7+ lymphoproliferative disorders and classic CLL immunophenotype patients.

Free
Allison Kagerer, Nikita Malakhov, Caitlin Keenan, Zhengming Chen, Amy Chadburn, Richard Furman, John Allan
Journal: Blood
Blood (2025) 146 (Supplement 1): 2121.
https://doi.org/10.1182/blood-2025-2121
Published: 2025
Journal Articles

Impact of FMC7 expression on baseline characteristics and outcomes in CLL patients treated with upfront BTKi monotherapy.

Free
Nikita Malakhov, Allison Kagerer, Caitlin Keenan, Zhengming Chen, Amy Chadburn, Richard Furman, John Allan
Journal: Blood
Blood (2025) 146 (Supplement 1): 2109.
https://doi.org/10.1182/blood-2025-2109
Published: 2025
Journal Articles

Zanubrutinib and venetoclax as initial therapy for CLL/SLL with obinutuzumab triplet consolidation in patients with detectable minimal residual disease (BruVenG).

Free
John Allan, Erin Mulvey, Daniel Helbig, Nikita Malakhov, Zhengming Chen, Brittany Hobbie, Sarah Nazir, Jerrod White, Zahra Grant, Jane Matejka, Simone Morris, Liming Bao, Peter Martin, Richard Furman
Journal: Blood
Blood (2025) 146 (Supplement 1): 3886.
https://doi.org/10.1182/blood-2025-3886
Published: 2025
Journal Articles

Phase II study of polatuzumab in combination with chemoimmunotherapy for richter transformation (PolaR-EPCH).

Free
John Allan, Andrew Lipsky, Seema Bhat, Suchitra Sundaram, Lubing Wu, Jane Matejka, Brittany Hobbie, Nourhan Hamadi, Simone Morris, Zhengming Chen, Ivo Sah Bander, Madhu Ouseph, Jia Ruan, Amy Chadburn, Adam Kittai, Richard Furman
Journal: Blood
Blood (2025) 146 (Supplement 1): 3681.
https://doi.org/10.1182/blood-2025-3681
Published: 2025
Journal Articles

Updated efficacy and safety results of the Bruton tyrosine kinase (BTK) degrader BGB-16673 in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) from the ongoing phase 1 CaDAnCe-101 study

Free
Inhye Ahn, Ricardo Parrondo, Meghan Thompson, Annamaria Frustaci, John Allan, Paolo Ghia, Irina Mocanu, Damien Roos Weil, Constantine Tam, Stephan Stilgenbauer, Judith Trotman, Lydia Scarfo, Nicole Lamanna, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, John Seymour
Journal: Blood
Blood (2025) 146 (Supplement 1): 85.
https://doi.org/10.1182/blood-2025-85
Published: 2025
Journal Articles

Distinct archetypes of clonal dynamics underlie response and resistance to diverse CLL therapies

Free
Marwan Kwok, Connor Johnson, Eugen Tausch, Liang Li, Chip Stewart, Carrie Cibulskis, Sam Pollock, Johanna van Vliet, Fanny Dao, Satyen Gohil, Madison Lee, Brian Danysh, Anke Schilhabel, Sandra Robrecht, Marc Zapatka, Emanuela Ghia, Laura Rassenti, Lita Freeman, Erica Bhavsar, Andy Itsara, Othman Al-Sawaf, John Allan, Richard Furman, Dan Avi Landau, Thomas Kipps, Adrian Wiestner, Matthias Ritgen, Kirsten Fischer, Barbara Eichhorst, Michael Hallek, Stephan Stilgenbauer, Ivana Bozic, Ignaty Leshchiner, Gad Getz, Catherine Wu
Journal: Blood
Blood (2025) 146 (Supplement 1): 245.
https://doi.org/10.1182/blood-2025-245
Published: 2025
Journal Articles

Co-mapping clonal and transcriptional heterogeneity in somatic evolution via got-multi.

Free
Minwoo Pak, Mirca Saurty-Seerunghen, Kellie Wise, Tsega-Ab Abera, Chhiring Lama, Neelang Parghi, Xiaotian Sun, Qi Gao, Liming Bao, Mikhail Roshal, John Allan, Richard Furman, Luciano Martelotto, Anna Nam
Journal: Blood
Blood (2025) 146 (Supplement 1): 244.
https://doi.org/10.1182/blood-2025-244
Published: 2025
Journal Articles

Preliminary efficacy and safety of the Bruton tyrosine kinase degrader BGB-16673 in patients with relapsed/refractory Richter transformation: Results from the ongoing phase 1 CaDAnCe-101 study

Free
Meghan Thompson, Annamaria Frustaci, John Seymour, John Allan, Paolo Ghia, Olivier Dumas, Franck Morschhauser, Martin Dreyling, Stephan Stilgenbauer, Inhye Ahn, Romain Guieze, Yanan Zhang, Linlin Xu, Kunthel By, Shannon Fabre, Daniel Persky, Amit Agarwal, Carlo Visco
Journal: Blood
Blood (2025) 146 (Supplement 1): 3895.
https://doi.org/10.1182/blood-2025-3895
Published: 2025
Journal Articles

National practice patterns and preferences in the use of fixed-duration vs. treat-to-progression therapies for CLL

Free
Tisheeka Graham, Tariqa Ackbarali, Catherine Coombs, John Allan
Journal: Blood
Blood (2025) 146 (Supplement 1): 8095.
https://doi.org/10.1182/blood-2025-8095
Published: 2025